Shire fends off AbbVie takeover bid


Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. AbbVie made three efforts at proposing a deal, with the largest worth around $27 billion (£16 billion) in a combination of cash and shares.

Shire’s board rejected the first two proposals outright, but met with AbbVie to clarify the terms of the third proposal, before once again rejecting it unanimously. Shire claimed in a statement that the offer ‘fundamentally undervalued Shire and its prospects as a leader in rare diseases and speciality markets’. Shire’s biggest selling product is Attention Deficit Hyperactivity Disorder drug Vyvanse (lisdexamfetamine), but in recent years it has built up a portfolio of treatments for rare diseases.

Shire’s board also expressed concerns about the tax structure of the deal, which would see the new company move its base to the UK – Shire is currently registered in Ireland, after relocating to benefit from reduced tax rates. In a filing with the US Securities and Exchange Commission, AbbVie confirmed that it is no longer in negotiations with Shire. However, that does not preclude further developments – under UK takeover rules, AbbVie now has until 18 July to make a firm offer for Shire, take its proposal direct to shareholders, or withdraw its interest.

This is the latest in a string of attempts to use mergers to escape the US tax regime. Pfizer failed in its bid to buy AstraZeneca, but device specialist Medtronic successfully wooed rival Covidien.


Related Content

Illumina fends off Roche hostile bid

27 January 2012 News Archive

news image

Roche aims to expand personalised medicine diagnostics by acquiring the gene sequencing leader

Takeover battle pushes Allergan to cut R&D jobs

28 July 2014 Business

news image

Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth

Most Read

No-frills coats set a trend for designer viruses

26 August 2014 Research

news image

An artificial protein that self-assembles around and protects DNA could be ideal for gene therapy, nanomachines and synthetic...

Rigid molecular wires make electrons fly

29 August 2014 Research

news image

Organic wires conduct electrons 800 times faster than other molecular counterparts by letting them hitch a ride on a vibratio...

Most Commented

Rigid molecular wires make electrons fly

29 August 2014 Research

news image

Organic wires conduct electrons 800 times faster than other molecular counterparts by letting them hitch a ride on a vibratio...

Concerns over chemical treatment of reclaimed fracking fluid

29 August 2014 Research

news image

Current recycling procedure may do more harm than good